JP Morgan Chase
KPTI icon

JP Morgan Chase’s Karyopharm Therapeutics KPTI Stock Holding History

JP Morgan Chase’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-764,600
Closed -$5M – 7606
2025
Q3 		$5M Buy
764,600
+755,100
+7,948% +$4.06M ﹤0.01% 3364
2025
Q2 		$40.9K Hold
9,500
– – ﹤0.01% 5990
2025
Q1 		$35.5K Buy
+9,500
New +$81.1K ﹤0.01% 5984

Other funds holding KPTI

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CCM
Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

JP Morgan Chase's KPTI Position: Q2 2026 in Review

JP Morgan Chase increased its Karyopharm Therapeutics (KPTI) stake by 43,978% in Q2 2026, buying an estimated $1.8M and bringing the position to 207,609 shares worth $2.09M. The position accounts for ﹤0.01% of the portfolio, ranked #4139.

JP Morgan Chase first reported a position in KPTI in Q4 2013 and has held it in 51 quarters since. The position peaked at $6.85M in Q4 2019. 97 funds tracked by Wall St. Rank hold KPTI as of Q2 2026.

  • JP Morgan Chase held 207,609 shares of Karyopharm Therapeutics worth $2.09M as of Q2 2026.
  • JP Morgan Chase bought 207,138 Karyopharm Therapeutics shares in Q2 2026, an estimated $1.8M.
  • Karyopharm Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #4139 holding.
  • JP Morgan Chase first reported a position in Karyopharm Therapeutics in Q4 2013 and has held it in 51 quarters since.
  • JP Morgan Chase's Karyopharm Therapeutics position peaked at $6.85M in Q4 2019.
  • 97 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.